Mr. Callow is a founder and Managing Partner of Boston Millennia Partners. Prior to forming Boston Millennia Partners, Mr. Callow co-founded Boston Capital Ventures in 1982 and is a Partner in four of its investment partnerships. Prior to that, he worked as a Senior Consultant at Braxton Associates, an international strategic planning firm that was organized by professionals from Boston Consulting Group and Bain & Co. His primary clients were Fortune 100 multinational companies where he advised senior management on strategic planning and implementing merger and acquisition strategies. Prior to his activity in the management consulting business, Mr. Callow worked in sales and marketing for Tymshare, Inc. a venture funded and subsequent public company in the cloud and remote computing sector which was acquired by McDonnell-Douglas.
In 1986, he was the founding institutional investor in PAREXEL International Corporation, and continues as its Presiding Director and Chair of the governance committee. (Nasdaq: PRXL). From its inception and seed funding with four employees, PAREXEL is now the third largest clinical research organization worldwide generating revenues in excess of $ 1.8 billion annually with approximately 15,000 employees in 70 countries.
He is a lead investor in, or has served as, a Director of a number of other public and private companies, including ILEX Oncology, Inc. (Nasdaq: ILXO), a cancer pharmaceutical company acquired by Genzyme for $1 billion; MedAptus, Inc., a mobile computing provider of clinical, financial and administrative software solutions to the medical community; and PHT Technologies, Inc., a provider of mobile and Web-based technology solutions to the pharmaceutical industry focused on patient outcomes and clinical trials management. Other investment responsibilities included Glycofi Inc., (acquired by Merck, NYSE: MRK); HotJobs, Inc. (acquired by Yahoo, NasdaqGS: YHOO); iVillage, Inc. (acquired by NBC Universal, a subsidiary of General Electric, NYSE: GE); and Tektagen, Inc. (acquired by Charles River Laboratories, NYSE: CRL). Mr. Callow manages investments in CardioMems, Inc, a cardiovascular heart sensor device for the treatment of congestive heart failure, Arthrosurface, Inc., a developer and manufacturer of advanced orthopedic devices and COTA, Inc. a cancer tracking and outcomes analytics company. Mr. Callow is a past Director of Jobs for Massachusetts, a Massachusetts based non-profit organization comprised of business and political leaders including Governors Mitt Romney and Deval Patrick.
Dana is a Member of the National Board of Directors of the Leukemia and Lymphoma Society, a non-profit organization with $ 300 million in revenues advancing the research and treatment of blood cancers worldwide. He currently chairs its Therapeutic Acceleration Program Committee. Dana is a member of the Board of Trustees and is the Chairman of the Investment Committee at Tufts University. He is on the Board of Overseers at Tufts University Medical School as well as the Tufts Technology Development & Commercialization Advisory Board. He has been a member of the Advisory Board of the Amos Tuck Center for Private Equity and Entrepreneurship at Dartmouth College since 1999.
Mr. Callow is a graduate of Tufts University and holds an MBA from the Amos Tuck School at Dartmouth College.